ALS Ltd (ASX: ALQ) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
ALS Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
ALS Ltd (ASX: ALQ)
Latest News
Share Market News
Strike Resources share price wanes despite moving closer to an off-take agreement
Share Market News
Why the ALS share price leapt 29% higher in July
Share Market News
These were the best performing ASX 200 shares in July
Share Gainers
These were the best performing shares on the ASX 200 in July
Share Market News
Why the ALS Ltd share price is up again today
Share Gainers
The best performing ASX 200 stock today may have more room to climb
Cheap Shares
Top brokers pick the latest ASX shares to buy today
Share Gainers
The ASX 200 stock hit by the Brazilian COVID-19 wave
Share Market News
ASX 200 up 0.1%: Big four banks rocket, Afterpay sinks lower
Share Gainers
Why ALS, Metcash, NAB, & Pointsbet shares are racing higher
Share Market News
5 things to watch on the ASX 200 on Wednesday
Share Gainers
Why ALS, Clover, Computershare, & EML Payments shares are storming higher
Frequently Asked Questions
-
Yes, ALS Ltd historically pays two partially or fully franked dividends a year.
-
ALS Ltd generally pays its shareholder dividends in July and December
-
ALS Ltd listed on the ASX on 18 July 1952.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
23 Nov 2023 | $0.1960 | 20.00% | Interim | 14 Dec 2023 |
09 Jun 2023 | $0.1940 | 10.00% | Final | 06 Jul 2023 |
24 Nov 2022 | $0.2030 | 0.00% | Interim | 16 Dec 2022 |
06 Jun 2022 | $0.1700 | 30.00% | Final | 04 Jul 2022 |
02 Dec 2021 | $0.1580 | 30.00% | Interim | 17 Dec 2021 |
07 Jun 2021 | $0.1460 | 70.00% | Final | 05 Jul 2021 |
26 Nov 2020 | $0.0850 | 100.00% | Interim | 16 Dec 2020 |
05 Jun 2020 | $0.0610 | 70.00% | Final | 06 Jul 2020 |
27 Nov 2019 | $0.1150 | 30.00% | Interim | 16 Dec 2019 |
03 Jun 2019 | $0.1150 | 35.04% | Final | 01 Jul 2019 |
29 Nov 2018 | $0.1100 | 20.00% | Interim | 18 Dec 2018 |
06 Jun 2018 | $0.0900 | 40.00% | Final | 02 Jul 2018 |
29 Nov 2017 | $0.0800 | 40.00% | Interim | 18 Dec 2017 |
07 Jun 2017 | $0.0000 | 0.00% | Final | 03 Jul 2017 |
05 Dec 2016 | $0.0550 | 60.00% | Interim | 21 Dec 2016 |
08 Jun 2016 | $0.0600 | 40.00% | Final | 01 Jul 2016 |
03 Dec 2015 | $0.0750 | 25.07% | Interim | 18 Dec 2015 |
11 Jun 2014 | $0.2000 | 50.00% | Final | 02 Jul 2014 |
07 Jun 2013 | $0.2700 | 50.00% | Final | 02 Jul 2013 |
05 Jun 2009 | $0.4250 | 0.00% | Final | 01 Jul 2009 |
01 Dec 2008 | $0.4250 | 58.82% | Interim | 17 Dec 2008 |
06 Jun 2008 | $0.5100 | 58.82% | Final | 01 Jul 2008 |
30 Nov 2007 | $0.2975 | 58.82% | Interim | 17 Dec 2007 |
06 Jun 2007 | $0.3570 | 58.82% | Final | 02 Jul 2007 |
29 Nov 2006 | $0.2380 | 58.82% | Interim | 15 Dec 2006 |
05 Jun 2006 | $0.2900 | 100.00% | Final | 03 Jul 2006 |
25 Nov 2005 | $0.2100 | 100.00% | Interim | 20 Dec 2005 |
04 Jun 2004 | $0.1900 | 100.00% | Final | 01 Jul 2004 |
28 Nov 2003 | $0.1400 | 100.00% | Interim | 19 Dec 2003 |
ALQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About ALS Ltd
ALS Ltd (ASX: ALQ) is one of the world's largest laboratory testing, inspection, certification, and verification businesses. It operates from around 350 sites across 65 countries.
Listed on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS's commodities segment traditionally generates the majority of the company's underlying earnings. It provides geochemistry, metallurgy, inspection, and mine site services for the mining industry globally.
The company also provides environmental, pharmaceutical, and food and beverage testing and certification. ALS Ltd has a multi-billion dollar market capitalisation and is part of the ASX 100.
ALQ Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
23 Apr 2024 | $13.27 | $-0.13 | -0.97% | 643,832 | $13.36 | $13.36 | $13.21 |
22 Apr 2024 | $13.40 | $0.36 | 2.76% | 752,617 | $13.14 | $13.47 | $13.12 |
19 Apr 2024 | $13.04 | $-0.26 | -1.95% | 826,791 | $13.25 | $13.25 | $12.81 |
18 Apr 2024 | $13.30 | $0.17 | 1.29% | 819,083 | $13.11 | $13.35 | $13.11 |
17 Apr 2024 | $13.13 | $0.00 | 0.00% | 329,669 | $13.20 | $13.23 | $13.10 |
16 Apr 2024 | $13.13 | $-0.16 | -1.20% | 1,801,791 | $13.20 | $13.29 | $13.04 |
15 Apr 2024 | $13.29 | $-0.12 | -0.89% | 689,398 | $13.44 | $13.45 | $13.22 |
12 Apr 2024 | $13.41 | $-0.02 | -0.15% | 1,508,224 | $13.29 | $13.46 | $13.25 |
11 Apr 2024 | $13.43 | $-0.06 | -0.44% | 760,078 | $13.24 | $13.50 | $13.24 |
10 Apr 2024 | $13.49 | $0.06 | 0.45% | 686,494 | $13.53 | $13.70 | $13.27 |
09 Apr 2024 | $13.43 | $0.14 | 1.05% | 1,057,540 | $13.21 | $13.48 | $13.21 |
08 Apr 2024 | $13.29 | $0.29 | 2.23% | 1,412,029 | $13.06 | $13.36 | $13.03 |
05 Apr 2024 | $13.00 | $-0.16 | -1.22% | 640,273 | $13.09 | $13.12 | $12.96 |
04 Apr 2024 | $13.16 | $0.19 | 1.46% | 629,730 | $13.16 | $13.24 | $12.85 |
03 Apr 2024 | $12.97 | $-0.01 | -0.08% | 606,370 | $12.97 | $13.07 | $12.89 |
02 Apr 2024 | $12.98 | $-0.15 | -1.14% | 906,344 | $12.55 | $13.13 | $12.50 |
28 Mar 2024 | $13.13 | $0.08 | 0.61% | 685,162 | $13.26 | $13.26 | $13.06 |
27 Mar 2024 | $13.05 | $0.14 | 1.08% | 1,601,745 | $12.88 | $13.12 | $12.77 |
26 Mar 2024 | $12.91 | $-0.16 | -1.22% | 2,420,428 | $12.92 | $12.98 | $12.54 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
19 Dec 2023 | Nigel Garrard | Buy | 3,150 | $40,477 |
On-market trade.
|
23 Nov 2023 | Nigel Garrard | Buy | 3,250 | $40,007 |
On-market trade.
|
26 Jul 2023 | Malcom Deane | Buy | 15,546 | $175,669 |
Conversion of securities.
|
26 Jul 2023 | Malcom Deane | Issued | 199,119 | $2,250,044 |
Issue of securities. 2,05,327 Rights, As per announcements on 04-08-2023
|
26 Jul 2023 | Malcom Deane | Exercise | 15,546 | $175,669 |
Conversion of securities. 40,514 Rights
|
06 Jun 2023 | Bruce Phillips | Buy | 50,000 | $58,401,243 |
On-market trade.
|
06 Jun 2023 | Peter Possemiers | Buy | 1,740 | $19,940 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Bruce John Phillips | Non-Executive DirectorNon-Executive Chairman | Aug 2015 |
Bruce Phillips was appointed a Non Executive Director of the Company on 1 August 2015 and became Chairman on 26 July 2016 following the 2016 Annual General Meeting. Bruce
is a qualified geophysicist with more than 40 years of technical, financial and managerial experience in the energy sector. |
Mr Nigel David Garrard | Non-Executive Director | Jun 2023 |
Mr Garrard is a former CEO and executive at ASX Listed Group and Divisional levels across the fast-moving consumer goods and industrial/manufacturing sectors. He has 20 years experience as an ASX-listed CEO across three companies. In 2019, he retired as Managing Director and CEO of Orora Limited leading its demerger from Amcor, and the subsequent listing of Orora Limited on ASX in 2013. He was President of the Amcor Australasia and Packaging Distribution business group, Managing Director of Coca-Cola Amatils Food and Services Division, and Managing Director of SPC Ardmona. He is currently a non-executive director of Ansell Limited, a non-executive director of CSR Ltd, Chairman of Flinders Port Holdings Pty. Ltd and Chairman of the McMahon Services advisory board. He has international operations, manufacturing and supply chain management experience in North America, New Zealand and Asia across food services and processing, primary products and packaging as well as marketing. Nigel also has M&A experience in Australia and offshore including acquisitions, divestments, joint ventures, demergers and mergers.
|
Dr John Francis Mulcahy | Non-Executive Director | Feb 2012 |
John Mulcahy was appointed a Non Executive Director of the Company in 2012. He is Chairman of Orix Australia Corporation Limited, an unlisted public company (appointed March 2016),
and Deputy Chairman of GWA Group Limited (appointed November 2010). He is also a current Non Executive Director of various Zurich Australia Insurance subsidiaries. John was previously a director and Chairman of both Mirvac Group Limited (November 2009 December 2022) and Coffey International Limited (September 2009 January 2016). |
Ms Tonianne Dwyer | Non-Executive Director | Jul 2016 |
Tonianne Dwyer was appointed a Non-Executive Director of the Company on 1 July 2016. She has significant experience as a company director and executive working in finance, corporate strategy and mergers and acquisitions across a variety of sectors and international markets.
|
Ms Leslie A Desjardins | Non-Executive Director | Nov 2019 |
Leslie Desjardins was appointed a Non-Executive Director of the Company on 21 November 2019. She has a background as a CFO and senior financial and governance professional in a range of large multinational and global businesses.
|
Dr Siddhartha Kadia | Non-Executive Director | Jan 2019 |
Siddhartha Kadia was appointed a Non Executive Director of the Company in January 2019. Siddhartha was formerly President and CEO of EAG Laboratories, a global scientific testing company headquartered in San Diego. He has also
been a Director of USA listed companies Newport Corporation (NSDQ: NEWP) and Volcano Corporation (NSDQ: VOLC). He is presently a Non-Executive Director of Nuvasive, Inc (appointed February 2022) and ATS (Applied Technical Services). |
Ms Erica Mann | Non-Executive Director | Mar 2024 |
Ms Mann has 30-year career in DAX, NYSE, NSDAQ pharmaceutical, OTC and FMCG. Before retiring as an executive, Erica led Bayers Consumer Health Division,. Prior to joining Bayer, Ms Mann was President and General Manager of Pfizer Nutrition following its acquisition of Wyeth Inc where she served as Senior Vice President of Global Nutrition. This followed other senior executive roles of other 500 companies including Eli-Lily and Johnson & Johnson. She has held leadership positions in South Africa, Australia, New Zealand, Germany, Switzerland and the US. In addition to her executive experience in the nutrition and health industry, Ms Mann has experience with global and emerging markets across Africa, China, Russia and Brazil. Currently Ms Mann serves as an independent director of Perrigo, DSM-Firmenich and Kellogg (recently reincorporated as Kellanova) where she is a member of the Talent, Audit, and Social Responsibility & Public Policy Committees. Ms Mann previously chaired the Board of the World Self-Medication Industry Association and as an independent director with Blackmores Ltd and Solo- Flordis International.
|
Mr Peter Possemiers | Non-Executive Director | Nov 2022 |
Peter Possemiers was appointed a NonExecutive Director of the Company on 1 November 2022.He has a background as a TIC sector expert with almost 40 years experience working as a Senior Executive in leadership roles globally for SGS. He has lead teams both regionally and globally most notably SGSs global Environment Health and Safety business, a CHF 550million business with a global headcount which exceeded 6000. As Executive Vice President, he was a member of the SGS Operations Council with responsibility for the strategic growth and profitability of the business, leading 15 strategic acquisitions.
|
Mr Malcom Deane | Chief Strategy Officer General Manager Life Sciences - Food & Pharma Americas GeneralChief Executive OfficerManaging Director | Mar 2023 |
Mr Deane researched legal frameworks on specific issues including corporate, insurance, agricultural and antitrust issues. Cooperated in merger control cases. He monitored status of torts, civil and commercial lawsuits in different courts. Also, served as a member of different teams of lawyers advising international clients on cross-border transactions, capital markets matters, structuring of GDN and ADR programs and project finance. He counseled clients on a wide range of commercial issues including contractual law, corporate law, secured transactions, consumer credits and agribusiness matters. Advised clients on wealth and estate planning matters
|
Mr Michael Paul Pearson | Company Secretary | Dec 2017 |
-
|
Michael Paul Pearson | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Paradice Investment Management Pty. Ltd. | 17,551,248 | 3.60% |
The Vanguard Group, Inc. | 16,378,763 | 3.40% |
Impax Asset Management Ltd | 15,988,593 | 3.30% |
State Street Global Advisors Australia Ltd. | 15,315,011 | 3.20% |
Capital Research Global Investors | 15,303,262 | 3.20% |
Schroder Investment Management (Australia) Ltd. | 13,603,883 | 2.80% |
Global Alpha Capital Management Ltd. | 13,191,624 | 2.70% |
Dnr Capital Pty Ltd | 10,957,501 | 2.30% |
First Sentier Investors (Growth) | 10,774,500 | 2.20% |
Northcape Capital Pty. Ltd. | 9,766,530 | 2.00% |
Macquarie Investment Management Global Ltd. | 9,513,704 | 2.00% |
Australian Foundation Investment Company Limited | 8,831,664 | 1.80% |
Baumber Gavin | 8,538,373 | 1.80% |
Blackrock Institutional Trust Company, N.A. | 8,488,776 | 1.60% |
Vanguard Investments Australia Ltd. | 7,634,493 | 1.60% |
Credit Suisse Asset Management | 7,147,120 | 1.50% |
Washington H. Soul Pattinson And Company Limited | 7,079,431 | 1.50% |
Vinva Investment Management Limited | 6,332,454 | 1.30% |
Greencape Capital Pty. Ltd. | 6,306,181 | 1.30% |
Plato Investment Management Limited | 5,971,208 | 1.20% |